Ross D Dolan1, Stephen T McSorley2, Paul G Horgan2, Barry Laird2, Donald C McMillan2. 1. Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom. Electronic address: Ross.Dolan@glasgow.ac.uk. 2. Academic Unit of Surgery, School of Medicine, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Abstract
INTRODUCTION: Cancer remains a leading cause of death worldwide. While a curative intent is the aim of any surgical treatment many patients either present with or go onto develop disseminated disease requiring systemic anti-cancer therapy with a palliative intent. Given their limited life expectancy appropriate allocation of treatment is vital. It is recognised that systemic chemoradiotherapy may shorten the quality/quantity of life in patients with advanced cancer. It is against this background that the present systematic review and meta-analysis of the prognostic value of markers of the systemic inflammatory response in patients with advanced cancer was conducted. METHODS: An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until the end of 2016. Titles were examined for relevance and studies relating to duplicate datasets, that were not published in English and that did not have full text availability were excluded. Full texts of relevant articles were obtained and were then examined to identify any further relevant articles. RESULTS: The majority of studies were retrospective. The systemic inflammatory response, as evidenced by a number of markers at clinical thresholds, was reported to have independent prognostic value, across tumour types and geographical locations. In particular, C-reactive protein (CRP, 63 studies), albumin (33 studies) the Glasgow Prognostic Score (GPS, 44 studies) and the Neutrophil Lymphocyte Ratio (NLR, 59 articles) were consistently validated across tumour types and geographical locations. There was considerable variation in the thresholds reported to have prognostic value when CRP and albumin were examined. There was less variation in the thresholds reported for NLR and still less for the GPS. DISCUSSION: The systemic inflammatory response, especially as evidenced by the GPS and NLR, has reliable prognostic value in patients with advanced cancer. Further prospective studies of their clinical utility in randomised clinical trials and in treatment allocation are warranted.
INTRODUCTION:Cancer remains a leading cause of death worldwide. While a curative intent is the aim of any surgical treatment many patients either present with or go onto develop disseminated disease requiring systemic anti-cancer therapy with a palliative intent. Given their limited life expectancy appropriate allocation of treatment is vital. It is recognised that systemic chemoradiotherapy may shorten the quality/quantity of life in patients with advanced cancer. It is against this background that the present systematic review and meta-analysis of the prognostic value of markers of the systemic inflammatory response in patients with advanced cancer was conducted. METHODS: An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until the end of 2016. Titles were examined for relevance and studies relating to duplicate datasets, that were not published in English and that did not have full text availability were excluded. Full texts of relevant articles were obtained and were then examined to identify any further relevant articles. RESULTS: The majority of studies were retrospective. The systemic inflammatory response, as evidenced by a number of markers at clinical thresholds, was reported to have independent prognostic value, across tumour types and geographical locations. In particular, C-reactive protein (CRP, 63 studies), albumin (33 studies) the Glasgow Prognostic Score (GPS, 44 studies) and the Neutrophil Lymphocyte Ratio (NLR, 59 articles) were consistently validated across tumour types and geographical locations. There was considerable variation in the thresholds reported to have prognostic value when CRP and albumin were examined. There was less variation in the thresholds reported for NLR and still less for the GPS. DISCUSSION: The systemic inflammatory response, especially as evidenced by the GPS and NLR, has reliable prognostic value in patients with advanced cancer. Further prospective studies of their clinical utility in randomised clinical trials and in treatment allocation are warranted.
Authors: David Hui; Carlos Eduardo Paiva; Egidio G Del Fabbro; Christopher Steer; Jane Naberhuis; Marianne van de Wetering; Paz Fernández-Ortega; Tatsuya Morita; Sang-Yeon Suh; Eduardo Bruera; Masanori Mori Journal: Support Care Cancer Date: 2019-03-13 Impact factor: 3.603
Authors: Arno Kornberg; Martina Schernhammer; Jennifer Kornberg; Helmut Friess; Katharina Thrum Journal: Dig Dis Sci Date: 2018-09-27 Impact factor: 3.199
Authors: Claribel Simmons; Donald C McMillan; Sharon Tuck; Cat Graham; Alistair McKeown; Mike Bennett; Claire O'Neill; Andrew Wilcock; Caroline Usborne; Kenneth C Fearon; Marie Fallon; Barry J Laird Journal: Oncologist Date: 2019-04-11
Authors: D Viñal; L Gutierrez-Sainz; D Martinez; J A Garcia-Cuesta; J Pedregosa; J Villamayor; L Ostios; D Sanchez-Cabrero; O Higuera; A Pinto; N Rodriguez-Salas; E Espinosa; J de Castro; J Feliu Journal: Clin Transl Oncol Date: 2020-11-23 Impact factor: 3.405
Authors: Ross D Dolan; Louise E Daly; Claribel Pl Simmons; Aoife M Ryan; Wei Mj Sim; Marie Fallon; Derek G Power; Andrew Wilcock; Matthew Maddocks; Michael I Bennett; Caroline Usborne; Barry J Laird; Donald C McMillan Journal: Cancers (Basel) Date: 2020-05-08 Impact factor: 6.639
Authors: Justin M Lebenthal; Junting Zheng; Paul A Glare; Eileen M O'Reilly; Andrew C Yang; Andrew S Epstein Journal: Cancer Date: 2021-01-20 Impact factor: 6.860